Issue 1/2014
Content (9 Articles)
Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer
Luís León, Roberto García-Figueras, Cristina Suárez, Antonia Arjonilla, Javier Puente, Blanca Vargas, Maria José Méndez Vidal, Carmen Sebastiá
Caffeic acid phenylethyl ester and MG132, two novel nonconventional chemotherapeutic agents, induce apoptosis of human leukemic cells by disrupting mitochondrial function
Victoria Cavaliere, Daniela L. Papademetrio, Tomás Lombardo, Susana N. Costantino, Guillermo A. Blanco, Elida M. C. Álvarez
EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer
Yogesh K. Vashist, Florian Trump, Florian Gebauer, Asad Kutup, Cenap Güngör, Viacheslav Kalinin, Rather Muddasar, Eik Vettorazzi, Emre F. Yekebas, Burkhard Brandt, Klaus Pantel, Jakob R. Izbicki
Delta-catenin promotes the proliferation and invasion of colorectal cancer cells by binding to E-cadherin in a competitive manner with p120 catenin
Hong Zhang, Shun-Dong Dai, Di Zhang, Dong Liu, Fang-Yuan Zhang, Tian-Yi Zheng, Ming-Ming Cui, Chao-Liu Dai
Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma
Laura M. Alwan, Kenneth Grossmann, Daniel Sageser, Joan Van Atta, Neeraj Agarwal, Jeffrey A. Gilreath
Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717–454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor
Swati Sikaria, Josefine Heim-Hall, Elizabeth H. Diaz, Ronald Williams, Kamelesh Sankhala, Brenda Laabs, Monica Mita
Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature
Amaury Daste, Marine Gross-Goupil, Sophie Roca, Jean-Christophe Bernhard, Alain Ravaud
Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer
Mark Sanford